References on Angiogenesis Research Using ALZET^® Osmotic Pumps

P8610 Dietrich,T., Onderka,J., Bock,F., Kruse,F.E., Vossmeyer,D., Stragies,R., Zahn,G., Cursiefen,C. Inhibition of Inflammatory Lymphangiogenesis by Integrin alpha 5 Blockade. American Journal of Pathology 2007; 171(-1-):361-372. >>> JSM6427; JSM6424; SC; Mice; 2 weeks; Controls received mp w/ vehicle; functionality of mp verified by mp and plasma levels analysis; dose-response (p. 368); pumps replaced after one week; half-life (p. 363) "rapid;" cardiovascular; immunology; animal info (BALB/C, 6 weeks old, suture-induced inflammatory corneal neovascularization); integrin a5B1 and avB3 antagonists; angiogenesis; lymphangiogenesis.

P8542 Sakai,T., Balasubramanian,K., Maiti,S., Haider,J.B., Schroit,A.J. Plasmin-cleaved beta-2-glycoprotein 1 is an inhibitor of angiogenesis. American Journal of Pathology 2007; 171(-5-):1659-1669. >>> Glycoprotein 1, B-2-; glycoprotein 1, nicked B-2-; SC; IP; Mice; 2002; 28 days; Controls received mp w/ HSA; cancer (prostate adenocarcinoma); peptides; multiple pumps per animal (2); animal info (male, C57BL/6, 6 weeks old); B2GP1 is also known as apolipoprotein H; mp implanted IP on day 1, SC on day 14, implanted pumps not removed.

P8520 Kumar,R., Knick,V.B., Rudolph,S.K., Johnson,J.H., Crosby,R.M., Crouthamel,M.C., Hopper,T.M., Miller,C.G., Harrington,L.E., Onori,J.A., Mullin,R.J., Gilmer,T.M., Truesdale,A.T., Epperly,A.H., Boloor,A., Stafford,J.A., Luttrell,D.K., Cheung,M. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. MOLECULAR CANCER THERAPEUTICS 2007; 6(-7-):2012-2021. >>> GW771806; SC; Mice (nude); mice (SCID); 2001; 5,6,21 days; Controls received mp w/ vehicle; dose-response (fig. 4); comparison of oral gavage vs. mp; cancer (colon); animal info (female, Swiss nu/nu, 8-12 weeks old); VEGFR inhibitor; "Continuous infusion of VEGFR inhibitor is more effective in controlling tumor growth and angiogenesis than p.o bolus dosing." (p. 2018).

P8512 Huang,Y., Chen,X., Dikov,M.M., Novitskiy,S.V., Mosse,C.A., Yang,L., Carbone,D.P. Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF. Blood 2007; 110(-2-):624-. >>> Vascular endothelial growth factor 165, recomb. human; vascular endothelial growth factor, receptor-2 selective; vascular endothelial growth factor, receptor-1 selective; Mice; 2004; 28 days; Controls received mp w/ PBS; cancer; peptides; animal info (female, Balb/c, 6-8 weeks old); angiogenesis; hematology.

P8511 Clarkson,A.N., Liu,H., Schiborra,F., Shaw,O., Sammut,I.A., Jackson,D.M., Appleton,I. Angiogenesis as a predictive marker of neurological outcome following hypoxia-ischemia. Brain Research 2007; 1171(--):111-121. >>> Clomethiazole; L-NAME; SC; Rat; 2ML1; 5 days; Controls received mp w/ vehicle or saline or no treatment; no stress (see pg. 112); enzyme inhibitor (NO synthase); ischemia (cerebral); animal info (male, Wistar, 21 days old).

P8366 Dorrell,M.I., Aguilar,E., Scheppke,L., Barnett,F.H., Friedlander,M. Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 2007; 104(-3-):967-972. >>> Vascular endothelial growth factor, aptamer; EMD472523; T2-TrpRS; PBS; CSF/CNS (intratumoral); Rat; 2001D; 2ML2; 2ML4; 3,6 days; 24 hours; Controls received mp w/ vehicle; cancer (gliosarcoma); animal info (male, Fischer, 344); EMD472523 is an integrin antagonist, VEGF aptamer is chemically identical to Macugen; T2 is a proteolytic fragment of tryptophan tRNA synthetase; all agents have angiostatic activity; tissue perfusion (tumor).

P8357 Mulder,W.J.M., van der Schaft,D.W.J., Hautvast,P.A.I., Strijkers,G.J., Koning,G.A., Storm,G., Mayo,K.H., Griffioen,A.W., Nicolay,K. Early in vivo assessment of angiostatic therapy efficacy by molecular MRI. FASEB Journal 2007; 21(-2-):378-383. >>> Endostatin; anginex; SC; Mice; 2 weeks; 3 days; Controls received mp w/ saline; cancer (melanoma); peptides; MRI; animal info (C57BL/6, 6 weeks old); antiangiogenesis.

P8302 Zhang,X.F., Connolly,C., Duquette,M., Lawler,J., Parangi,S. Continuous administration of the three thrombospondin-1 type 1 repeats recombinant protein improves the potency of therapy in an orthotopic human pancreatic cancer model. Cancer Letters 2007; 247(-1-):143-149. >>> Thrombospondin-1, three type 1 repeats; PBS; SC; Mice (SCID); 1007D; 7 days; Controls received mp w/ vehicle; comparison of IP injections vs. mp; stability verified by incubation in pump, 7 days; cancer (pancreatic); peptides; animal info (female, SCID, 4-6 weeks old); antiangiogenesis therapy; 3TSR; "Continuous administration of 3TSR reduced dosage and improved therapeutic potency." p. 146.

P8275 Tanabe,K., Maeshima,Y., Ichinose,K., Kitayama,H., Takazawa,Y., Hirokoshi,K., Kinomura,M., Sugiyama,H., Makino,H. Endostatin peptide, an inhibitor of angiogenesis, prevents the progression of peritoneal sclerosis in a mouse experimental model. Kidney International 2007; 71(-3-):227-238. >>> Endostatin (1-27), human; PBS; SC; Mice; 2004; 24 days; Controls received mp w/ vehicle; dose-response (fig. 1); no stress (see pg. 234); animal info (male, ICR, female, 6 weeks old, 27 grams, peritoneal sclerosis); "Continuous administration of endostatin peptide via subcutaneous osmotic minipumps did not produce any harmful side effects...In addition, treatment with endostatin peptide did not give rise to any pathological alterations in the heart, liver, or kidney, and failed to affect wound repair" (p. 234); nephrology.

P8226 Michaud-Levesque,J., Demeule,M., Beliveau,R. In vivo inhibition of angiogenesis by a soluble form of melanotransferrin. Carcinogenesis 2007; 28(-2-):280-288. >>> Melanotransferrin, soluble, truncated recomb. human; melanotransferrin, [125I]-soluble, truncated recomb. human; Ringers's solution; HEPES solution; SC; Mice (nude); 1007D; 7 days; Controls received mp w/ vehicle; dose-response (fig. 6); comparison of SC injections vs. mp; half-life (p. 285) ~7.6 hours + or - 0.9 hours; cancer; peptides; animal info (female, athymic CD-1-nuBr, 5-10 weeks old); "The use of ALZET osmotic pump infusion technique provided a higher therapeutic efficacy as compared with repeated S.C. injections, emphasizing the advantages of constant infusion rather than pulse-dose drug inputs for antiangiogenic effects." (p. 287).

R0235 Folkman,J. Angiogenesis. Annual Review of Medicine 2006; 57(--):1-18. >>> Endostatin, recomb.; IP; Mice; ; Cardiovascular; ALZET see pg. 8.

P8346 Otsuka,H., Akashi,H., Murohara,T., Okazaki,T., Shintani,S., Tayama,K., Sasaki,K., Imaizumi,T., Aoyagi,S. The prostacyclin analog beraprost sodium augments the efficacy of therapeutic angiogenesis induced by autologous bone marrow cells. Annals of Vascular Surgery 2006; 20(-5-):646-652. >>> Beraprost, sodium; Saline; isotonic; SC; Rabbit; 4 weeks; Controls received mp w/ vehicle; cardiovascular; ischemia (hindlimb); animal info (male, New Zealand white, 2.4-2.6 kg).

P8294 Yagi,H., Ueda,M., Jinno,H., Aiura,K., Mikami,S., Tada,H., Seno,M., Yamada,H., Kitajima,M. Anti-tumor effect in an in vivo model by human-derived pancreatic RNase with basic fibroblast growth factor insertional fusion protein through antiangiogenic properties. CANCER SCIENCE 2006; 97(-12-):1315-1320. >>> Fibroblast growth factor, basic; CL-RFN89; PBS; Mice (nude); ; Cancer (carcinoma); animal info (4 weeks old, female, Balb/C, nude); antiangiogenesis; tumor cells in right flank, agent is an insertional-fusion protein.

P8288 Capoccia,B.J., Shepherd,R.M., Link,D.C. G-CSF and AMD3100 mobilize monocytes into the blood that stimulate angiogenesis in vivo through a paracrine mechanism. Blood 2006; 108(-7-):2438-2445. >>> Granulocyte colony-stimulating factor, recomb. human; PBS; SC; Mice; mice (transgenic); 5, 7 days; Controls received mp w/ vehicle; cardiovascular; peptides; ischemia (hind limb); animal info (C57BL/6, 8-10 weeks old); ischemia; acute vascular injury.

P8163 Boodhwani,M., Mieno,S., Voisine,P., Feng,J., Sodha,N., Li,J., Sellke,F.W. High-dose atorvastatin is associated with impaired myocardial angiogenesis in response to vascular endothelial growth factor in hypercholesterolemic swine. Journal of Thoracic and Cardiovascular Surgery 2006; 132(-6-):1299-1306. >>> Vascular endothelial growth factor 165, recomb. human; Heparin; Perivascular (circumflex coronary artery); Mini-pig; 2ML4; 4 weeks; Cardiovascular; peptides; ischemia (cardiac); animal info (male, female, yucatan, 20-30 kg, 23 weeks old).

P8109 Dirkx,A.E.M., Egbrink,M.G.A.O., Castermans,K., van der Schaft,D.W.J., Thijssen,V.L.J.L., Dings,R.P.M., Kwee,L., Mayo,K.H., Wagstaff,J., Steege,J.C.A.B., Griffioen,A.W. Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. FASEB Journal 2006; 20(-6-):621-630. >>> Anginex; endostatin; BSA; angiostatin; Saline; SC; Mice; 2 weeks; 7, 11 days; Controls received mp w/ BSA or no treatment; dose-response (fig.5); cancer (melanoma, colon carcinoma); animal info (C57BL/6).

P7904 Harding,T.C., Lalani,A.S., Roberts,B.N., Yendluri,S., Luan,B., Koprivnikar,K.E., Gonzalez-Edick,M., Guang,H.T., Musterer,R., VanRoey,M.J., Ozawa,T., LeCouter,R.A., Deen,D., Dickinson,P.J., Jooss,K. AAV serotype 8-mediated gene delivery of a soluble VEGF receptor to the CNS for the treatment of glioblastoma. MOLECULAR THERAPY 2006; 13(-5-):956-966. >>> Adeno-associated virus serotype 8 vector, recomb.; CSF/CNS (intratumoral); Rat; 2001D; 24 hours; Controls received mp w/ AAV control; cancer (glioblastoma multiforme, u-251 MG); gene thrapy; animal info (male, athymic, 6 wk. old); rAAV contains soluble VEGF inhibitor, sVEGFR1/R2; "Implantation of the mini pump allows the slow infusion of a rAAV vector...to transduce more effectively the intracranial tumor mass." (pg. 962); antiangiogenesis.

P7748 Huang,X.L., Brown,C., Ni,W.H., Maynard,E., Rigby,A.C., Oettgen,P. Critical role for the Ets transcription factor ELF-1 in the development of tumor angiogenesis. Blood 2006; 107(-8-):3153-3160. >>> Peptide A1; peptide A1, mutant; PBS; SC; Mice (nude); 10,14 days; Controls received mp w/ vehicle; no stress (see pg. 3157); cancer (B16 melanoma); peptides; animal info (C57BL/6, female); peptide A1 is composed of ETS sequences and a 12-amino acid HIV-TAT protein-transducing membrane peptide.

P7608 Xia,C.F., Yin,H., Borlongan,C.V., Chao,J., Chao,L. Postischemic infusion of adrenomedullin protects against ischemic stroke by inhibiting apoptosis and promoting angiogenesis. Experimental Neurology 2006; 197(-2-):521-530. >>> Adrenomedullin, human; calcitonin gene-related peptide (8-37); Saline; SC; Rat; 7, 14 days; Controls received mp w/ vehicle; cardiovascular; peptides; ischemia (cerebral); animal info (male, Sprague-Dawley 220 g); middle cerebral artery occlusion; "continuous and longterm infusion of AM starting at day 1 after I/.

P7437 Grunewald,M., Avraham,I, Dor,Y, Bachar-Lustig,E  Cell 2006; 124(--):175-189. >>> AMD 3100; Sodium bicarbonate; Mice; 14 days; Controls received mp w/ saline; angiogenesis.

P7326 Kishore,R., Qin,G.J., Luedemann,C., Bord,E., Hanley,A., Silver,M., Gavin,M., Goukassain,D., Losordo,D.W. The cytoskeletal protein ezrin regulates EC proliferation and angiogenesis via TNF-alpha-induced transcriptional repression of cyclin A. Journal of Clinical Investigation 2005; 115(-7-):1785-1796. >>> Uridine, bromodeoxy-; Mice (nude); 7 days; Cardiovascular; ischemia (hindlimb); labeling of ischemic hind limb muscle.

P7322 Dings,R.P.M., Williams,B.W., Song,C.W., Griffioen,A.W., Mayo,K.H., Griffin,R.J. Anginex synergizes with radiation therapy to inhibit tumor growth by radiosensitizing endothelial cells. International Journal of Cancer 2005; 115(-2-):312-319. >>> Anginex; PBS; SC; Mice (nude); 2002; 2004; 2, 4 weeks; Controls received mp w/ vehicle; comparison of IP injections vs. mp; no stress (see pg. 315); half-life (p. 318) 50-90 min. in mice; cancer (ovarian, mammary carcinoma); toxicology; peptides; irradiation 5 Gy once per week or 25 Gy one time tumo-bearing legs; angiogenesis inhibitor; "continuous infusion of anginex in combination with weekly irradiation resulted in tumor regression and impalpable tumors by the end of treatment." P317.

P7307 Nakagawa,K., Sasaki,Y., Kato,S., Kubodera,N., Okano,T. 22-oxa-1alpha,25-dihydroxyvitamin D3 inhibits metastasis and angiogenesis in lung cancer. Carcinogenesis 2005; 26(-6-):1044-1054. >>> Vitamin D3, 1, 25-dihydroxy-; vitamin D3, 22-oxa-la, 25-dihydroxy-; Tween 20; ethanol; SC; Mice; 2ML4; 3 weeks; 10, 18 days; Controls received mp w/ vehicle; dose-response; cancer (lung carcinoma); 10% ethanol; millipore chamber ring; sc dorsal air sac model.

P7248 Lakka,S.S., Gondi,C.S., Dinh,D.H., Olivero,W.C., Gujrati,M., Rao,V.H., Sioka,C., Rao,J.S. Specific interference of urokinase-type plasminogen activator receptor and matrix metalloproteinase-9 gene expression induced by double-stranded RNA results in decreased invasion, tumor growth, and angiogenesis in gliomas. Journal of Biological Chemistry 2005; 280(-23-):21882-21892. >>> RNA, small interfering; RNA, small interfering, uPAR; RNA, small interfering, MMP-9; CSF/CNS; Mice (nude); 1002; 2 weeks; Controls received mp w/ PBS or empty vector; cancer (glioblastoma); siRNA is within a plasmid vector (pUM vector); antiangiogenesis; gene therapy.

P7233 Haviv,F., Bradley,M.F., Kalvin,D.M., Schneider,A.J., Davidson,D.J., Majest,S.M., McKay,L.M., Haskell,C.J., Bell,R.L., Nguyen,B., Marsh,K.C., Surber,B.W., Uchic,J.T., Ferrero,J., Wang,Y.C., Leal,J., Record,R.D., Hodde,J., Badylak,S.F., Lesniewski,R.R., Henkin,J. Thrombospondin-1 mimetic peptide inhibitors of angiogenesis and tumor growth: Design, synthesis, and optimization of pharmacokinetics and biological activities. Journal of Medicinal Chemistry 2005; 48(-8-):2838-2846. >>> ABT-510; Dextrose solution; water; SC; Mice; 2001; 7, 14 days; Controls received mp w/ vehicle; dose-response (fig. 6); half-life (p. 2838); cancer (lung carcinoma); peptides.

P7179 Jacobi,J., Sydow,K., von Degenfeld,G., Zhang,Y., Dayoub,H., Wang,B.Y., Patterson,A.J., Kimoto,M., Blau,H.M., Cooke,J.P. Overexpression of dimethylarginine dimethylaminohydrolase reduces tissue asymmetric dimethylarginine levels and enhances angiogenesis. Circulation 2005; 111(-11-):1431-1438. >>> L-NAME; dimethylarginine, asymmetric; PBS; SC; IP; Mice; mice (transgenic); 2002; 2004; 2, 3 weeks; Controls received mp w/ vehicle; enzyme inhibitor (nitric oxide synthase); cardiovascular; ischemia (hindlimb).

P7136 Bandyopadhyay,A., Wang,L., Loepz-Casillas,F., Mendoza,V., Yeh,I.T., Sun,L.Z. Systemic administration of a soluble betaglycan suppresses tumor growth, angiogenesis, and matrix metalloproteinase-9 expression in a human xenograft model of prostate cancer. PROSTATE 2005; 63(-1-):81-90. >>> Transforming growth factor-B3 receptor, recomb. soluble; PBS; SC; Mice (nude); 2002; 14 days; Controls received mp w/ vehicle; comparison of IP injections vs. mp; no stress (see pg. 84,88); cancer (prostate); multiple pumps per animal (2).

P6908 Alonso,G., Galibert,E., Duvoid-Guillou,A., Vincent,A. Hyperosmotic stimulus induces reversible angiogenesis within the hypothalamic magnocellular nuclei of the adult rat: a potential role for neuronal vascular endothelial growth factor. BMC NEUROSCIENCE 2005; 6(--):U1-U19. >>> Antibody, anti-vascular endothelial growth factor; PBS; CSF/CNS (supraoptic nucleus); Rat; 1007D; 6 days; Schematic fig 9; 10 mm, 26 gauge cannula used.

P7075 Thijssen,V.L.J.L., Brandwijk,R.J.M.G., Dings,R.P.M., Griffioen,A.W. Angiogenesis gene expression profiling in xenograft models to study cellular interactions. Experimental Cell Research 2004; 299(-2-):286-293. >>> Anginex; Saline; SC; Mice (nude); 2004; 20 days; Controls received mp w/ vehicle; cancer (melanoma, ovarian carcinoma).

P7037 Lei,L., Zhou,R.F., Zheng,W., Christensen,L.P., Weiss,R.M., Tomanek,R.J. Bradycardia induces angiogenesis, increases coronary reserve, and preserves function of the postinfarcted heart. Circulation 2004; 110(-7-):796-802. >>> Alinidine; Rat; 3,7,21 days; Controls received mp w/ vehicle; ischemia (cardiac); cardiovascular; echocardiograph (ECG); KaTp channel antagonist.

P6913 Apte,R.S., Barreiro,R.A., Duh,E., Volpert,O., Ferguson,T.A. Stimulation of neovascularization by the anti-angiogenic factor PEDF. INVESTIGATIVE OPHTHALMOLOGY&VISUAL SCIENCE 2004; 45(-12-):4491-4497. >>> Pigment epithelium-derived growth factor; antibody, anti-PEDF; SC; Mice; 2001; 7 days; Dose-response (4492, 4495); peptides; PEDF; "...we decided to use a subcutaneously implanted pump to deliver PEDF to circumvent any effects on angiogenesis as a result of iatrogenic trauma." (p. 4492); antiangiogenesis.

P6834 Hashiya,N., Jo,N., Aoki,M., Matsumoto,K., Nakamura,T., Sato,Y., Ogata,N., Ogihara,T., Kaneda,Y., Morishita,R. In vivo evidence of angiogenesis induced by transcription factor ets-1 - Ets-1 is located upstream of angiogenesis cascade. Circulation 2004; 109(-24-):3035-3041. >>> Antibody, anti-vascular endothelical growth factor; antibody, immunoglobulin G, rabbit; IP; Mice; ; Cardiovascular; ischemia.

P6792 Norrby,K. Human apo-lactoferrin enhances angiogenesis mediated by vascular endothelial growth factor A in vivo. JOURNAL OF VASCULAR RESEARCH 2004; 41(-4-):293-304. >>> Lactoferrin, human apo-; Saline; SC; Rat; 2001; 7 days; Controls received mp w/ vehicle; dose-response (table 5); comparison of ingestion vs. mp; half-life (p. 295) estimated at 3.3 hours; cardiovascular; agent is a multifunctional iron and heparin binding protein.

P6774 Bello,L., Lucini,V., Costa,F., Pluderi,M., Giussani,C., Acerbi,F., Carrabba,G., Pannacci,M., Caronzolo,D., Grosso,S., Shinkaruk,S., Colleoni,F., Canron,X., Tomei,G., Deleris,G., Bikfalvi,A. Combinatorial administration of molecules that simultaneously inhibit angiogenesis and invasion leads to increased therapeutic efficacy in mouse models of malignant glioma. Clinical Cancer Research 2004; 10(-13-):4527-4537. >>> PEX, recomb. human; PF-4/CTF; P4-4/DLR; vascular endothelial growth inhibitor, cyclo-; Water, sterile; SC; Mice; mice (nude); 2004; 28, 112, 140 days; Dose-response; long-term study; pumps replaced every 28 days; no stress (see pg. 4532); cancer (glioma); peptides; "The treatment was always very well tolerated without the occurrence of any side effects." (p. 4532); angiogenesis inhibitor.

P6720 Gondi,C.S., Lakka,S.S., Dinh,D.H., Olivero,W.C., Gujrati,M., Rao,J.S., Rao,J.S. RNAi-mediated inhibition of cathepsin B and uPAR leads to decreased cell invasion, angiogenesis and tumor growth in gliomas. ONCOGENE 2004; 23(--):8486-8496. >>> RNA, small interfering; EV/SV vector; PBS; CSF/CNS (intratumoral); Mice (nude); ; Controls received mp w/ vehicle; tissue perfusion (tumor); cancer (glioma); gene therapy; antiangiogenesis; siRNA (cathepsin B); pump model not stated (0.25 ul/hr); "...local intracranial delivery of pcu using mini-osmotic pumps effectively inhibited human malignant glioma growth.".

P6634 Croll,S.D., Ransohoff,R.M., Cai,N., Zhang,Q., Martin,F.J., Wei,T., Kasselman,L.J., Kintner,J., Murphy,A.J., Yancopoulos,G.D., Wiegand,S.J. VEGF-mediated inflammation precedes angiogenesis in adult brain. Experimental Neurology 2004; 187(-2-):388-402. >>> Vascular endothelial growth factor 164, mouse; Flt-Fc; angiopoietin I, human; angiopoietin II, human; PBS; CSF/CNS (frontoparietal cortex); Rat; 2002; 1,2,3,4,5,7 days; Controls received mp w/ vehicle or hFc; dose-response (fig. 1); brain tissue distribution; peptides; cyanoacrylate adhesive (Loctite 495).

P6633 Tsutsumi,N., Yonemitsu,Y., Shikada,Y., Onimaru,M., Tanii,M., Okano,S., Kaneko,K., Hasegawa,M., Hashizume,M., Maehara,Y., Sueishi,K. Essential role of PDGFR alpha-p70S6K signaling in mesenchymal cells during therapeutic and tumor angiogenesis in vivo - Role of PDGFR alpha during angiogenesis. Circulation Research 2004; 94(-9-):1186-1194. >>> Antibody, polyclonal anti-PDGF-AA; IP; Mice; 1007D; 2001; 7 days; Cancer; cardiovascular.

P6618 Lakka,S.S., Gondi,C.S., Yanamandra,N., Olivero,W.C., Dinh,D.H., Gujrati,M., Rao,J.S. Inhibition of cathepsin B and MMP-9 gene expression in glioblastoma cell line via RNA interference reduces tumor cell invasion, tumor growth and angiogenesis. ONCOGENE 2004; 23(-27-):4681-4689. >>> RNA, small interfering; human cytomegalovirus promoter; Empty vector; CSF/CNS; Mice; 2004; 5 weeks; Cancer (glioblastoma); siRNA against mmp-9 and cathepsin; antiangiogenesis; gene therapy.

P6576 Khatri,J.J., Johnson,C., Magid,R., Lessner,S.M., Laude,K.M., Dikalov,S.I., Harrison,D.G., Sung,H.J., Rong,Y., Galis,Z.S. Vascular oxidant stress enhances progression and angiogenesis of experimental atheroma. Circulation 2004; 109(-4-):520-525. >>> Ebselen; DMSO; SC; Mice (transgenic); 14 days; Controls received mp w/ vehicle; cardiovascular; 50% DMSO; ebselen is a glutathione peroxidase-mimetic antioxidant (a.k.a Harmokisane).

P6564 Suzuki,O., Bishop,A.T., Sunagawa,T., Katsube,K., Friedrich,P.F. VEGF-promoted surgical angiogenesis in necrotic bone. MICROSURGERY 2004; 24(-1-):85-91. >>> Vascular endothelial growth factor 165; Phosphate buffer; albumin rabbit serum; Bone; Rabbit; 1003D; 3 days.

P6556 Nap,A.W., Griffioen,A.W., Dunselman,G.A.J., Bouma-Ter Steege,J.C.A., Thijssen,V.L.J.L., Evers,J.L.H., Groothuis,P.G. Antiangiogenesis therapy for endometriosis. Journal of Clinical Endocrinology and Metabolism 2004; 89(-3-):1089-1095. >>> Endostatin; anginex; SC; Mice (nude); 1002; 2 weeks; Controls received SC saline daily; no stress (see pg.1092); peptides; "The angiostatic agents did not appear to affect the overall health of the mice...The behavior of the mice during treatments was normal as well." (p. 1092).

P6498 Nakamura,E.S., Koizumi,K., Kobayashi,M., Saiki,I. Inhibition of lymphangiogenesis-related properties of murine lymphatic endothelial cells and lymph node metastasis of lung cancer by the matrix metalloproteinase inhibitor MMI270. CANCER SCIENCE 2004; 95(-1-):25-31. >>> MMI270; DMSO; PEG 300; IP; Mice; 2004; 15 days; Controls received mp w/ vehicle; no stress (see pg.27); enzyme inhibitor (matrix metalloproteinase); cancer (lung); MMI270 was formerly termed CGS27023A; 50% DMSO "The continuous administration of MMI270 for 15 days using an osmotic pump led to a significant decrease in the weight of tumor-metastasized lymph nodes" (p. 29).

P6370 Manoonkitiwongsa,P.S., Schultz,R.L., McCreery,D.B., Whitter,E.F., Lyden,P.D. Neuroprotection of ischemic brain by vascular endothelial growth factor is critically dependent on proper dosage and may be compromised by angiogenesis. Journal of Cerebral Blood Flow and Metabolism 2004; 24(-6-):693-702. >>> Vascular endothelial growth factor; Saline; IA (carotid); Rat; 2001; 7 days; Controls received mp w/ vehicle; dose response (p. 697); stroke; ischemia (cerebral); biocompatible glue was used to secure catheter in artery.

P6352 Akhtar,N., Padilla,M.L., Dickerson,E.B., Steinberg,H., Breen,M., Auerbach,R., Helfand,S.C. Interleukin-12 inhibits tumor growth in a novel angiogenesis canine hemangiosarcoma xenograft model. NEOPLASIA 2004; 6(-2-):106-116. >>> Interleukin-12; PBS; SC; Mice (SCID); 2004; 1 week; Controls received mp w/ vehicle; functionality of mp verified by pump explantation, examination and tumor reduction; cancer (Hemangiosarcoma); peptides; pump model not listed; tumor cells from a canine.

P5950 Schmidt,N.O., Ziu,M., Carrabba,G., Giussani,C., Bello,L., Sun,Y.P., Schmidt,K., Albert,M., Black,P.M., Carroll,R.S. Antiangiogenic therapy by local intracerebral microinfusion improves treatment efficiency and survival in an orthotopic human glioblastoma model. Clinical Cancer Research 2004; 10(-4-):1255-1262. >>> Endostatin, recomb. murine; PBS; CSF/CNS (intratumoral); Mice (nude); 2004; 21 days; Controls received mp w/ vehicle; functionality of mp verified by residual volume; comparison of SC injections vs. chronic ICV mp; no stress (see pg. 1261); cancer (glioma); ALZET brain infusion kit 1 used (per Dr. Carroll); MRI; "The direct infusion of therapeutic compounds into brain tumors can overcome some of the obstacles of drug delivery." p. 1255; BIK's removed prior to MRI; "no signs of intracranial bleeding due to the presence of the pumps or antiangiogenic treatment were observed..." (p. 1261); angiogenesis inhibitor; surgical glue used to affix cannula to the skull.

R0182 Mayo,K.H., Griffioen,A.W. Designing beta pep peptides: a rational approach to the discovery of n ovel pharmaceutical agents and small molecules. DRUGS OF THE FUTURE 2003; 28(-4-):337-346. >>> Anginex; PBS; SC; Mice (nude); 14,28 days; comparison of SC injections vs. mp; cancer (melanoma, colon, ovarian); peptides; angiogenesis inhibitor; "administration of anginex by osmotic mini-pumps gave the best results, compared to loco-regional injections, once-or-twice-daily subcutaneous injections or slow release alginate strategies." (p. 341).

P7704 Cattaneo,M.G., Pola,S., Deho,V., Sanguini,A.M., Vicentini,L.M. Alprostadil suppresses angiogenesis in vitro and in vivo in the murine Matrigel plug assay. Br.J.Pharmacol. 2003/1; 138(-2-):377-385. >>> Prostaglandin E1; cyclodextrin; Saline, isotonic; SC; Mice; 4 days; Controls received mp w/ vehicle; animal info (C57/BL6, female, 6-8 weeks old).

P7697 Stoeltzing,O., Liu,W., Reinmuth,N., Fan,F., Parry,G.C., Parikh,A.A., McCarty,M.F., Bucana,C.D., Mazar,A.P., Ellis,L.M. Inhibition of integrin alpha beta 1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice. Int.J.Cancer 2003/4/20; 104(-4-):496-503. >>> Fluorouracil, 5-; Saline; IP; Mice; 2002; 2 weeks; Controls received mp w/ vehicle; cancer; angiogenesis; "In preliminary studies..., we observed severe side effects with 5-FU...biweekly injections...thus, we chose to deliver 5-FU by continuous infusion...to minimize toxicity. Additionally, studies have demonstrated an increased efficacy of chemotherapeutic agents when administered continuously." (p. 497).

P6636 Dings,R.P.M., van der Schaft,D.W.J., Hargittai,B., Haseman,J., Griffioen,A.W., Mayo,K.H. Anti-tumor activity of the novel angiogenesis inhibitor anginex. Cancer Letters 2003; 194(-1-):55-66. >>> Anginex; PBS; albumin, human serum; SC; Mice (nude); 2004; 28 days; Dose-response; cancer (ovarian); angiogenesis inhibitor; comparison of once or twice daily injections; alginate beads and minipumps; "Of the three administrative routes used (daily loco-regional bolus injections, continuous systemic delivery via osmotic mini-pumps and suspension in alginate beads implanted subcutaneously), continuous systemic administration of the peptide worked best." (p. 63).

P6609 Cheng,N., Brantley,D., Bin Fang,W., Liu,H., Fanslow,W., Cerretti,D.P., Bussell,K.N., Reith,A.D., Jackson,D., Chen,J. Inhibition of VEGF-dependent multistage carcinogenesis by soluble EphA receptors. NEOPLASIA 2003; 5(-5-):445-456. >>> EphA2-Fc, soluble receptor; EphA3-Fc, soluble receptor; immunoglobulin G; IP; Mice (transgenic); 2002; 2 weeks; Controls received mp w/ vehicle; drug plasma levels taken; comparison of IP bolus injections vs. IP mp; cancer (carcinoma); "...In comparison to bolus IP injection, continuous administration of angiogenesis inhibitors by an osmotic pump implanted IP resulted in a decrease of the required dosage and improved the effectiveness of therapy." p. 451.

P6134 Reijneveld,J.C., Taphoorn,M.J.B., Kerckhaert,O.A.J., Drixler,T.A., Boogerd,W., Voest,E.E. Angiostatin prolongs the survival of mice with leptomeningeal metastases. European Journal of Clinical Investigation 2003; 33(-1-):76-81. >>> Angiostatin; Water, distilled; SC; Mice; 2001; 7 days; Controls received mp w/ vehicle; cancer (melanoma); angiogenesis inhibitor; "angiostatin was administered through a continuous infusion...the continuous administration of angiogenesis inhibitors has greater therapeutic efficacy then the more commonly used twice-daily injections." p. 80.

P6050 Martin,T.A., Parr,C., Davies,G., Watkins,G., Lane,J., Matsumoto,K., Nakamura,T., Mansel,R.E., Jiang,W.G. Growth and angiogenesis of human breast cancer in a nude mouse tumour model is reduced by NK4, a HGF/SF antagonist. Carcinogenesis 2003; 24(-8-):1317-1323. >>> NK4; Hepatocyte factor/scatter factor; BSA; SC; Mice (nude); 2004; 4 weeks; Controls received mp w/ vehicle; cancer (breast); peptides; NK4 is a hepatocyte growth factor/scatter factor (HGF/SF) antagonist; angiogenesis research.

P6038 Sarlos,S., Rizkalla,B., Moravski,C.J., Cao,Z.M., Cooper,M.E., Wilkinson-Berka,J.L. Retinal angiogenesis is mediated by an interaction between the angiotensin type 2 receptor, VEGF, and angiopoietin. American Journal of Pathology 2003; 163(-3-):879-887. >>> PD123319; IP; Rat (neonate); 2004; ; Controls received mp w/ vehicle; animal info (11 days old).

P6036 Zhu,B.Q., Heeschen,C., Sievers,R.E., Karliner,J.S., Parmley,W.W., Glantz,S.A., Cooke,J.P. Second hand smoke stimulates tumor angiogenesis and growth. CANCER CELL 2003; 4(-3-):191-196. >>> Mecamylamine; cerivastatin; SC; Mice; 17 days; Enzyme inhibitor (HMG-coA reductase).

P6000 Dings,R.P.M., Yokoyama,Y., Ramakrishnan,S., Griffioen,A.W., Mayo,K.H. The designed angiostatic peptide anginex synergistically improves chemotherapy and antiangiogenesis therapy with angiostatin. Cancer Research 2003; 63(-2-):382-385. >>> Anginex; Bpep28; PBS; SC; Mice (nude); 2004; 28 days; Controls received mp w/ vehicle; dose-response (fig.1, p. 383); cancer (ovarian); peptides; anginex is a potent angiogenesis inhibitor; Bpep28 is a control peptide without antiangiogenic activity.

P5999 Mayo,K.H., Dings,R.P.M., Flader,C., Nesmelova,I., Hargittai,B., van der Schaft,D.W.J., van Eijk,L.I., Walek,D., Haseman,J., Hoye,T.R., Griffioen,A.W. Design of a partial peptide mimetic of anginex with antiangiogenic and anticancer activity. Journal of Biological Chemistry 2003; 278(-46-):45746-45752. >>> Anginex; 6DBF7; PBS; albumin, human serum; SC; Mice (nude); 2004; 28 days; Controls received mp w/ vehicle; cancer (ovarian); peptides; angiogenesis inhibitors.

P5997 Kuroiwa,M., Takeuchi,T., Lee,J.H., Yoshizawa,J., Hirato,J., Kaneko,S., Choi,S.H., Suzuki,N., Ikeda,H., Tsuchida,Y. Continuous versus intermittent administration of human endostatin in xenografted human neuroblastoma. Journal of Pediatric Surgery 2003; 38(-10-):1499-1505. >>> Endostatin, recomb. human; Saline; SC; Mice (nude); 1003D; 3 days; Controls received 3 mp w/ vehicle; comparison of SC injections vs. mp; no stress (see p. 1501); cancer (neuroblastoma); angiogenesis inhibitor; multiple pumps per animal (3); picture of nude mouse w/3 pumps (fig.1; p. 1500); "The set of 3 osmotic pumps was retained successfully in the subcutaneous tissue of the treated and control animals throughout the experiment, no decrease in body weight was observed in either group." (p. 1501).

P5946 Zilberberg,L., Shinkaruk,S., Lequin,O., Rousseau,B., Hagedorn,M., Costa,F., Caronzolo,D., Balke,M., Canron,X., Convert,O., Lain,G., Gionnet,K., Goncalves,M., Bayle,M., Bello,L., Chassaing,G., Deleris,G., Bikfalvi,A. Structure and inhibitory effects on angiogenesis and tumor development of a new vascular endothelial growth inhibitor. Journal of Biological Chemistry 2003; 278(-37-):35564-35573. >>> CBO-p11; PBS; SC; Mice (nude); 2004; 28,58 days; Controls received mp w/ vehicle; long-term study; pumps replaced every 28 days for the long-term study; cancer (glioma); CBO-p11 is a cyclo-VEGI inhibitor; angiogenesis inhibitor.

P5943 Wada,N., Otani,Y., Kubota,T., Kimata,M., Minagawa,A., Yoshimizu,N., Kameyama,K., Saikawa,Y., Yoshida,M., Furukawa,T., Fujii,M., Kumai,K., Okada,Y., Kitajima,M. Reduced angiogenesis in peritoneal dissemination of gastric cancer through gelatinase inhibition. CLINICAL&EXPERIMENTAL METASTASIS 2003; 20(-5-):431-435. >>> Marimastat; DMSO; water; SC; Mice (SCID); 2002; 2 weeks; controls received mp w/ vehicle; enzyme inhibitor (matrix metalloprotease); marimastat, the broad-spectrum matrix metalloproteinase inhibitor was dissolved in 50% DMSO; angiogenesis inhibitor.

P5940 Davies,G., Mason,M.D., Martin,T.A., Parr,C., Watkins,G., Lane,J., Matsumoto,K., Nakamura,T., Jiang,W.G. The HGF/SF antagonist NK4 reverses fibroblast- and HGF-induced prostat e tumor growth and angiogenesis in vivo. International Journal of Cancer 2003; 106(-3-):348-354. >>> Hepatocyte growth factor; NK4; BSA; SC; Mice (nude); 2004; 28 days; Controls received mp w/ vehicle; cancer (prostate); NK4 (HGF/SF antagonist) is recomb. human.

P5929 Namba,T., Koike,H., Murakami,K., Aoki,M., Makino,H., Hashiya,N., Ogihara,T., Kaneda,Y., Kohno,M., Morishita,R. Angiogenesis induced by endothelial nitric oxide synthase gene through vascular endothelial growth factor expression in a rat hindlimb ischemia model. Circulation 2003; 108(-18-):2250-2257. >>> Immunoglobulin G; antibody, anti-vascular endothelial growth factor; IP; Rat; 28 days; Cardiovascular; peptides; pump model not stated; ischemia (hind-limb).

P5918 Matsuo,Y., Li,Y.T., Taniguchi,H., Motoda,M., Amemiya,T. Inhibition of experimental choroidal neovascularization by an anti-growth agent inhibiting vascular endothelial development. Japanese Journal of Ophthalmology 2003; 47(-5-):454-458. >>> FR-118487; Propylene gylcol; SC; Rat; 2002; 2 weeks; FR-118487 is an angiogenesis inhibitor.

P5819 Giussani,C., Carrabba,G., Pluderi,M., Lucini,V., Pannacci,M., Caronzolo,D., Costa,F., Minotti,M., Tomei,G., Villani,R., Carroll,R.S., Bikfalvi,A., Bello,L. Local intracerebral delivery of endogenous inhibitors by osmotic minipumps effectively suppresses glioma growth in vivo. Cancer Research 2003; 63(-12-):2499-2505. >>> Platelet factor-4; MMP-2 (hemopexin fragment); PBS; SC; CSF/CNS (intratumoral); Mice; 2004; 28 or 94 days; Controls received mp w/ PBS; tissue perfusion (tumor); dose-response (p.2502); comparison of IP injections SC systemic mp infusion vs. local intracranial mp infusion; long-term study; pumps replaced after 28 days in some groups; stability verified by in vitro assay; cancer (glioma); Angiogenesis inhibitors; COOH terminal fragment of PF-4 used; In vitro activity of agents confirmed for up to 16 days; "In conclusion, our data demonstrates that local intracerebral delivery of endogenous inhibitors by osmotic minipumps is a very effective modality for the treatment of aggressive tumors..." (p.2505); tissue perfusion (tumor);.

P5731 Sun,Y.J., Jin,K.L., Xie,L., Childs,J., Mao,X.O., Logvinova,A., Greenberg,D.A. VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia. Journal of Clinical Investigation 2003; 111(-12-):1843-1851. >>> Uridine, bromodeoxy-; Saline; SC; Rat; 3 days.

P5637 Francis,D.J., Parish,C.R., McGarry,M., Santiago,F.S., Lowe,H.C., Brown,K.J., Bingley,J.A., Hayward,I.P., Cowden,W.B., Campbell,J.H., Campbell,G.R., Chesterman,C.N., Khachigian,L.M. Blockade of vascular smooth muscle cell proliferation and intimal thickening after balloon injury by the sulfated oligosaccharide PI-88 - Phosphomannopentaose sulfate directly binds FGF-2, blocks cellular signaling, and inhibits proliferation. Circulation Research 2003; 92(-8-):E70-E77. >>> PI-88; Saline; SC; IP; Rat; rabbit; 2ML2; 2 weeks; Controls received mp w/ vehicle; enzyme inhibitor (heparanase); cardiovascular; PI-88 is a synthetic polysulfated oligosaccharide (also called phosphomannopentaose sulfate); potent inhibitor of tumor metastasis and angiogenesis; pumps implanted SC in rats and IP in rabbits..

P5515 Casanova,M.L., Blazquez,C., Martinez-Palacio,J., Villanueva,C., Fernandez-Acenero,M.J., Huffman,J.W., Jorcano,J.L., Guzman,M. Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. J.Clin.Invest 2003; 111(-1-):43-50. >>> JWH-133; WIN-55,212-2; PBS; BSA; SC; Mice (nude); 2002; 11 days; Controls received mp w/ vehicle; cancer; cannabinoid agonists.

R0231 Freedman,S.B., Isner,J.M. Therapeutic angiogenesis for coronary artery disease. Ann.Intern.Med. 2002/1/1; 136(-1-):54-71. >>> Vascular endothelial growth factor; Periadventitial; Pig; 3,4 weeks; Replacement therapy (coronary ligation); cardiovascular; ischemia (cardiac); review, pg. 59.

P6176 van der Schaft,D.W.J., Dings,R.P.M., De Lussanet,Q.G  FASEB J 2002; 16(--):1991-1993. >>> Anginex; Saline; SC; Mice; 14 days; Controls received mp w/ vehicle; dose-response (fig. 4a); cancer (melanoma, ovarian); peptides; Anginex is a 33-mer cytokine-like peptide; potent angiogenesis inhibitor.

P5978 Luttun,A., Tjwa,M., Moons,L., Wu,Y., Angelillo-Scherrer,A., Liao,F., Nagy,J.A., Hooper,A., Priller,J., De Klerck,B., Compernolle,V., Daci,E., Bohlen,P., Dewerchin,M., Herbert,J.M., Fava,R., Matthys,P., Carmeliet,G., Collen,D., Dvorak,H.F., Hicklin,D.J., Carmeliet,P. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nature Medicine 2002; 8(-8-):831-840. >>> Placental growth factor; vascular endothelial growth factor; SC; Mice; 2001; 7 days; Angiogenesis.

P5820 Sorensen,D.R., Leirdal,M., Iversen,P.O., Sioud,M. Combination of endostatin and a protein kinase C alpha DNA enzyme improves the survival of rats with malignant glioma. NEOPLASIA 2002; 4(-6-):474-479. >>> Platelet factor 4 peptides; PBS; CSF/CNS (intratumoral); Mice (nude); 2004; 28 days; Controls received mp w/ vehicle; tissue perfusion (intratumoral); dose-response (p. 6888; fig 6); cancer; peptides; glioma; antiangiogenesis..

P5458 Coxon,A., Bolon,B., Estrada,J., Kaufman,S., Scully,S., Rattan,A., Duryea,D., Hu,Y.L., Rex,K., Pacheco,E., Van,G., Zack,D., Feige,U. Inhibition of interleukin-1 but not tumor necrosis factor suppresses neovascularization in rat models of corneal angiogenesis and adjuvant arthritis. Arthritis and Rheumatism 2002; 46(-10-):2604-2612. >>> Interleukin-1 receptor antagonist; Saline; sodium citrate; EDTA; Tween 80; SC; Rat; 2ML1; 7 days; Controls received mp w/ BSA "to control for nonspecific anti-angiogenic effects of stress associated with implantation of the osmotic minipump." (p. 2605); implantation of pumps delivering BSA caused no angiogenesis.

P5342 Velde,E.A.T., Vogten,J.M., Gebbink,M.F.G.B., van Gorp,J.M., Voest,E.E., Rinkes,I.H.M.B. Enhanced antitumour efficacy by combining conventional chemotherapy with angiostatin or endostatin in a liver metastasis model. British Journal of Surgery 2002; 89(-10-):1302-1309. >>> Angiostatin; SC; Mice; 2001; ; Cancer; angiogenesis inhibitor.

P5340 Scholz,D., Ziegelhoeffer,T., Helisch,A., Wagner,S., Friedrich,C., Podzuweit,T., Schaper,W. Contribution of arteriogenesis and angiogenesis to postocclusive Hindlimb perfusion in mice. Journal of Molecular and Cellular Cardiology 2002; 34(-7-):775-787. >>> Fibroblast growth factor 2; PBS; IA (femoral); Mice; 1007D; ; Controls received mp w/ vehicle; peptides.

P5248 Wongtrakul,S., Bishop,A.T., Friedrich,P.F. Vascular endothelial growth factor promotion of neoangiogenesis in conventional nerve grafts. J Hand Surg.[Am.] 2002/3; 27(-2-):277-285. >>> Vascular endothelial growth factor; PBS; Albumin, rabbit serum; CSF/CNS (sciatic nerve); Rabbit; 1003D; 3 days; Controls received mp w/ vehicle; tissue perfusion (sciatic nerve graft); peptides; human recomb. VEGF used; transplantation;.

P5200 Silvestre,J.S., Tamarat,R., Senbonmatsu,T., Icchiki,T., Ebrahimian,T., Iglarz,M., Besnard,S., Duriez,M., Inagami,T., Levy,B.I. Antiangiogenic effect of angiotensin II type 2 receptor in ischemia- induced angiogenesis in mice hindlimb. Circ.Res 2002/5/31; 90(-10-):1072-1079. >>> Angiotensin II; Mice (Knockout); 2004; 28 days; Controls received no pump; peptides; ischemia (hind-limb).

P5055 Sasaki,K., Murohara,T., Ikeda,H., Sugaya,T., Shimada,T., Shintani,S., Imaizumi,T. Evidence for the importance of angiotensin II type 1 receptor in ischemia-induced angiogenesis. Journal of Clinical Investigation 2002; 109(-5-):603-611. >>> Vascular Endothelial Growth Factor; PBS; Albumin, bovine serum; CSF/CNS; CSF/CNS (cortex); CSF/CNS (third ventricle); rat; 2001; ; controls received mp w/ vehicle; dose response (p. 591); half-life = 6 min. (p. 594); peptides; brain tissue distribution; VEGF was human recombinant; benefits of continuous infusion p. 594.

P5052 te Velde,E.A., Voest,E.E., van Gorp,J.M., Verheem,A., Hagendoorn,J., Gebbink,M.F., Rinkes,I.H.B. Adverse effects of the antiangiogenic agent angiostatin on the healing of experimental colonic anastomoses. ANNALS OF SURGICAL ONCOLOGY 2002; 9(-3-):303-309. >>> Angiostatin; PBS; SC; mice; 2001; 4-7 days; controls received mp w/ vehicle; stability by mouse cornea neovascularization assay (p. 304); cancer; wound healing; angiogenesis inhibitor.

P5039 Iversen,P.O., Iversen,P.O., Sorensen,D.R., Benestad,H.B. Inhibitors of angiogenesis selectively reduce the malignant cell load in rodent models of human myeloid leukemias. LEUKEMIA 2002; 16(--):376-381. >>> Endostatin; PI-88; IP; mice; 2004; 4 weeks; cancer; recombinant human endostatin used; PI-88 is an anticoagulant mannopentaose phosphate sulfate; angiogenesis inhibitors. Agents given singly or concomitantly in same pump.

R0222 Ng,Y.S, D'Amore,P.A  Current Controlled Trials in Cardiovascular Medicine 2001; 2(-6-):278-285. >>> Vascular endothelial growth factor; Pig; ; Cardiovascular; peptides; MRI; ALZET pumps mentioned on pg. 279.

P7114 Carmeliet,P., Moons,L., Luttun,A., Vincenti,V., Compernolle,V., De Mol,M., Wu,Y., Bono,F., Devy,L., Beck,H., Scholz,D., Ackerk,T., DiPalma,T., Dewerchin,M., Noel,A., Stalmans,I., Barra,A., Blacher,S., VandenDriessche,T., Ponten,A., Eriksson,U., Plate,K.H., Foidart,J.M., Schaper,W., Charnock-Jones,S., Hicklin,D.J., Herbert,J.M., Collen,D., Persico,M.G. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nature Medicine 2001; 7(-5-):575-583. >>> Placental growth factor-1, recomb. human; Mice; 2001; 7 days; Controls received mp w/ vehicle; replacement therapy (PgF -/- mice); cardiovascular; ischemia (retinal); embryology.

P6178 Swiercz,R, Keck,R.W, Skrzypcak-Jankun,E, Selman,S.H, Jankun,J  Oncology Reports 2001; 8(--):463-470. >>> Plasminogen activator inhibitor-1; Saline; SC; Mice (SCID); 2004; 28 days; Controls received mp w/ saline; dose-response (fig. 4 and 5); cancer (prostate); angiogenesis inhibitor.

P5798 Malcontenti-Wilson,C., Muralidharan,V., Skinner,S., Christophi,C., Sherris,D., O'Brien,P.E. Combretastatin A4 prodrug study of effect on the growth and the microvasculature of colorectal liver metastases in a murine model.. Clin Cancer Res 2001; 7(-4-):1052-1060. >>> Combretastatin A4P; PBS; SC; Mice; 1002; 14 days; Comparison of IP injections vs. mp; cancer (colorectal); combretastatin A4P (CA4P) is a prodrug that binds to tubulin microtubules of capillary endothelial cells; angiogenesis inhibitor.

P5758 Stern,J.W., Fang,J., Shusterman,S., Pierson,G., Barr,R., Pawel,B., Diller,L., Grupp,S.A. Angiogenesis inhibitor TNP-470 during bone marrow transplant: safety in a preclinical model. Clin Cancer Res 2001; 7(-4-):1026-1032. >>> INP-470; Saline; IP; Mice (transgenic); 1002; 14 days; Controls received mp w/ vehicle; comparison of bolus injections vs. chronic mp; cancer; TNP-470 is an angiogenesis inhibitor; pump used to overcome the short half life of TNP-470 (p. 1030).

P5030 Kisker,O., Becker,C.M., Prox,D., Fannon,M., D'Amato,R., Flynn,E., Fogler,W.E., Sim,B.K., Allred,E.N., Pirie-Shepherd,S.R., Folkman,J. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res 2001/10/15; 61(-20-):7669-7674. >>> Endostatin; Sodium citrate; Sodium phosphate; IP; mice (SCID); mice; 2001; 14, 24, 32 days; controls received mp w/ vehicle; functionality of mp verified by serum endostatin levels; dose-response (p.7673, Fig. 4); comparison of SC and IP bolus injections vs. continuous infusion w/ mp; pumps replaced every 7 days; endostatin stability verified by in vitro biologic activity after 1-7 day implantation; half-life (p. 7669) of endostation in mice after SC bolus is ~10 hrs.; cancer; angiogenesis inhibitor; recomb. human endostatin used; continuous administration of human endostatin resulted in increased efficacy and an 8-10-fold decrease in dose required to achieve the same effect as daily bolus administration.

P4991 Tanaka,T., Konno,H., Baba,S., Kanai,T., Matsumoto,K., Matsuda,I., Ohba,K., Ohta,M., Kamiya,K., Nakamura,S. Prevention of hepatic and peritoneal metastases by the angiogenesis inhibitor FR-118487 after removal of growing tumor in mice. Japanese Journal of Cancer Research 2001; 92(--):88-94. >>> Endothelin-1; SC; IP; rat; 2002; 1, 2, or 4 weeks; ET-1 infused at a subpressor dose of 2 pmol/kg/min; ischemia (hind-limb); cardiovascular.

P4657 Drixler,T.A, Rinkes,I.H.M.B, Ritchie,E.D, van Vroonhoven,T.J.M.V, Gebbink,M.F.B.G, Voest,E.E  Cancer Research 2000; 60(--):1761-1765. >>> Angiostatin; PBS; SC; mice; 2001; 2002; 7, 14 days; Controls received mp w/ vehicle; dose-response (p. 1763); comparison of SC injections vs. mp; half-life (p. 1761); cancer; angiogenesis inhibitor; this study shows that continuous administration of angiostatin significantly improves inhibition of angiogenesis and tumor growth supression compared to injections.

P3851 Powell,J.A., Mohamed,S.N., Kerr,J.S., Mousa,S.A. Antiangiogenesis efficacy of nitric oxide donors. Journal of Cellular Biochemistry 2000; 80(--):104-114. >>> Penicillamine, S-nitroso N-acetyl-; Glutathione, S-nitroso N-acetyl;; Saline; SC; mice; 2002; 14 days; controls received mp w/ vehicle; SNAP and SNAG are nitric oxide donors; angiogenesis inhibitors..

R0158 Laham,R.J., Hung,D., Simons,M. Therapeutic myocardial angiogenesis using percutaneous intrapericardial drug delivery. Clin.Cardiol. 1999/1; 22(-1 Suppl 1-):I6-I9. >>> Fibroblast growth factor, basic; Vascular endothelial growth factor; Heparin; Intrapericardial space; Perivascular (coronary circumflex artery); Rabbit; Pig; ; Cardiovascular; peptides; review of various models of intrapericardial drug administration; 50 units of heparin.

P8196 Heymans,S., Luttun,A., Nuyens,D., Theilmeier,G., Creemers,E., Moons,L., Dyspersin,G.D., Cleutjens,J.P., Shipley,M., Angellilo,A., Levi,M., Nube,O., Baker,A., Keshet,E., Lupu,F., Herbert,J.M., Smits,J.F., Shapiro,S.D., Baes,M., Borgers,M., Collen,D., Daemen,M.J., Carmeliet,P. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat.Med. 1999/10; 5(-10-):1135-1142. >>> Vascular endothelial growth factor 165, recomb. human; SC; Mice; 2001; 7 days; Controls received no treatment; cardiovascular; peptides; ischemia (cardiac); animal info (8-12 weeks old); myocardial infarction by coronary artery ligation.

P4375 Rosenstein,J.M., Mani,N., Silverman,W.F., Krum,J.M. Patterns of brain angiogenesis after vascular endothelial growth factor administration in vitro and in vivo. Proc.Natl.Acad.Sci.USA 1998/6; 95(--):7086-7091. >>> Vascular endothelial growth factor;; PBS;; CSF/CNS (cortex);; rat;; 2001;; 7 days;; controls received mp with vehicle; peptides;.

P4294 Kido,A., Tsujiuchi,T., Morishita,T., Tsutsumi,M., Takahama,M., Miyauchi,Y., Mii,Y., Tamai,S., Konishi,Y. Telomerase activity correlates with growth of transplantable osteosarcomas in rats treated with cis-diammine dichloroplatinum or the angiogenesis inhibitor AGM-1470. Jpn.J.Cancer Res. 1998/10; 89(--):1074-1081. >>> AGM-1470;; Ethanol;; SC;; rat;; 2ML4;; 2 weeks;; controls received mp w/ vehicle; cancer; O-(chloroacetylcarbamoyl) fumagillol (AGM-1470) is an antiangiogenic agent;.

P5546 Morishita,T., Mii,Y., Miyauchi,Y., Miura,S., Honoki,K., Aoki,M., Kido,A., Tamai,S., Tsutsumi,M., Konishi,Y. Efficacy of CDDP and AGM-1470 chemotherapy against lung metastasis in rat osteosarcoma depends on the timing of combined administration. Jpn.J.Clin.Oncol. 1997/8; 27(-4-):236-239. >>> AGM-1470; SC; Rat; 2002; 14 days; Cancer, AMG-1470 is also called fumagillol; angiogenesis inhibitor; fumagillin analog; transplantation.

P6181 Morishita,T, Mii,Y., Miyauchi,Y., Miura,S., Honoki,K., Aoki,M., Kido,A., Tamai,S., Tsutsumi,M., Konishi,Y. Efficacy of the Angiogenesis inhibitor O-(chloroacetyl-carbamoyl)fumagillol (AGM-1470) on Osteosarcoma Growth and Lung Metastasis in Rats. Jpn.J.Clin.Oncol. 1995; 25(--):25-31. >>> AGM-1470; Ethanol; SC; Rat; 2ML4; 4 weeks; Comparison of SC injections vs. SC mp; 100% ethanol used; ALZAID kit incorrectly used to verify ethanol compatibility. The ALZAID chemical compatibility kit will not produce reliable results with ethanol; through manufacturer testing, only 15% ethanol is compatible with the ALZET pumps..

P4477 Voest,E.E, Kenyon,B.M, O'Reilly,M.S, Truitt,G, D'Amato,R.J, Folkman,J  Journal of the National Cancer Institute 1995; 87(-8-):581-586. >>> Interferon-gamma; Saline; IM; Mice (scid); 2002; ; Controls received mp w/ saline; functionality of mp verified by checking residual volume; comparison of bolus invections vs. mp; cancer; immunology; angiogenesis inhibitor; recomb. murine interferon-gamma used; "... in comparison with bolus injections, continuous intraperitoneal infusion of IFN gamma achieved enhanced inhibition of angiogenesis ..." (p. 585).

P3995 Oliver,S.J., Cheng,T.P., Banquerigo,M.L., Brahn,E. Suppression of collagen-induced arthritis by an angiogenesis inhibitor, AGM-1470, in combination with cyclosporin: reduction of vascular endothelial growth factor (VEGF). Cellular Immunol. 1995; 166(--):196-206. >>> Cyclosporin A; PEG 300; SC; rat; 2ML4; no duration posted; photo of rat showing implanted pump (pg. 204); no stress (see pp. 199, 204, 205); immunology; controls received sham surgeries.

P2901 Landau,C., Jacobs,A.K., Haudenschild,C.C. Intrapericardial basic fibroblast growth factor induces myocardial angiogenesis in a rabbit model of chronic ischemia. Am.Heart J. 1995; 129(--):924-931. >>> Fibroblast growth factor; Angiotensin II; BSA; PBS; IV (external jugular); intrapericardial; rabbit; 2ML4; 1, 1-4 weeks; controls received mp with saline instead of AII or mp with albumin instead of bFGF; stability of bFGF verified previously at 37 degrees C for up to four weeks when dispensed from a sequestered source; good methods (p.926); IV dose of 200 U of heparin given with implantation of iv pump; pump exposed after 2 weeks to verify continuation of accurate placement in pericardium; recomb. basic FGF used; peptides; ischemia (cardiac).

P2490 Soubrane,G., Cohen,S.Y., Delayre,T., Tassin,J., Hartmann,M.-P., Coscas,G.J., Courtois,Y., Jeanny,J.-C. Basic fibroblast growth factor experimentally induced choroidal angiogenesis in the minipig. Curr.Eye Res. 1994; 13(--):183-195. >>> Fibroblast growth factor; PBS; Eye (suprachoroidal space); mini-pig; 2001; no duration posted; stability verified by biological activity assay (p 185-6) after 4 days; peptides; spatial distribution of exogenous FGF examined (p 188); basic FGF used.

P2261 Fajardo,L.F., Kwan,H.H., Kowalski,J., Prionas,S.D., Allison,A.C. Dual role of tumor necrosis factor-a in angiogenesis. Am.J.Pathol. 1992; 140(--):539-544. >>> Tumor necrosis factor-a; PBS; SC; mice; 2002; 14 days; controls received mp w/PBS; peptides; pump implanted within 5mm of disc angiogenesis system (DAS); recomb. murine TNF used.

P1391 Eppley,B., Doucet,M., Connolly,D., Feder,J. Enhancement of angiogenesis by bFGF in mandibular bone graft healing in the rabbit. J.Oral Maxillofac.Surg. 1988; 46(-5-):391-398. >>> Fibroblast growth factor; Saline; Albumin, rabbit serum; bone (mandible); rabbit; 2001; 2002; 14 days; bilateral tissue perfusion of the mandible; peptides; basic FGF used.

top of page